<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2034">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05134688</url>
  </required_header>
  <id_info>
    <org_study_id>Magnesium sulphate in PPROM</org_study_id>
    <nct_id>NCT05134688</nct_id>
  </id_info>
  <brief_title>Magnesium Sulphate in Premature Rupture of Membranes</brief_title>
  <official_title>Magnesium Sulphate for Tocolysis in Preterm Prelabour Rupture of Membranes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the outcome of using magnesium sulphate on fetus and women with preterm premature&#xD;
      rupture of membranes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preterm premature rupture of membranes (PPROM) is defined as rupture of the chorioamniotic&#xD;
      membranes before the onset of labor prior to 37 weeks of gestation. Approximately 1% to 5% of&#xD;
      pregnancies are complicated by PPROM . PPROM contributes to perinatal morbidity and&#xD;
      mortality, secondary to premature birth, and maternal morbidity. Overall, PPROM accounts for&#xD;
      about one-third of all preterm births . In order to reduce the effects of prematurity, early&#xD;
      PPROM (24 to 33 weeks) is best served with conservative management in the absence of labor,&#xD;
      infection, or fetal distress . The conservative management of PPROM consists of the use of&#xD;
      antibiotic treatment and antenatal steroid to enhance fetal lung maturity . With or without&#xD;
      the presence of labor, it is unclear whether tocolysis of women with PPROM would be&#xD;
      efficacious in reducing the consequences of prematurity .The use of tocolytics in women with&#xD;
      PPROM is still controversial. Many physicians use tocolytic therapy as a prophylactic measure&#xD;
      and others initiate tocolysis only with the onset of contractions. There is also a variety of&#xD;
      options for tocolysis: betamimetics, calcium channel blockers, cyclo-oxygenase (COX)&#xD;
      inhibitors, oxytocin receptor antagonists and magnesium sulphate . As betamimetis is not&#xD;
      available and isn't used in our country and magnesium sulphate is available magnesium&#xD;
      sulphate is used widly. The loading dose of magnesium sulphate is IV 4 gm over 20 minutes&#xD;
      followed by 1gm/hour for 6 hours The potential benefit from increased latency due to&#xD;
      tocolysis must be weighed against the potential harm in increased maternal and perinatal&#xD;
      infection, the latter of which can possibly lead to long-term sequelae for the child,&#xD;
      including cerebral palsy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 21, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Latency period after rupture of membranes</measure>
    <time_frame>Baseline</time_frame>
    <description>Measure letancy period between prelabour rupture of membranes and delivery during using magnesium sulphate as a tocolytic and without using magnesium sulphate</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Premature Rupture of Membrane</condition>
  <arm_group>
    <arm_group_label>Grup 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group receive magnesium sulphate IV(4gm loading dose over 20 minutes followed by 1gm /hour for 6 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Receive no further treatment than conservative mangement( antibiotics and steroids)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate</intervention_name>
    <description>Tocolytic to stop preterm labor</description>
    <arm_group_label>Grup 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pregnant women with gastational age between 28 weeks and 36 weeks and 6 days who are&#xD;
             diagnosed with preterm prelabour rupture of membranes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  clinical suspicion of chorioamnionitis&#xD;
&#xD;
          -  Patients refusal to participate in clinical research.&#xD;
&#xD;
          -  significant vaginal bleeding&#xD;
&#xD;
          -  previous tocolysis use after rupture of membranes&#xD;
&#xD;
          -  nonreassuring fetal heart tracing&#xD;
&#xD;
          -  fetal anomalies&#xD;
&#xD;
          -  significant maternal medical complications, and maternal or fetal indication for&#xD;
             delivery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Fathi</last_name>
    <phone>01002058742</phone>
    <email>Ahmedalfathi94@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diaa eldeen Abdelaal</last_name>
    <phone>01005212137</phone>
    <email>Abdelaald@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Parry S, Strauss JF 3rd. Premature rupture of the fetal membranes. N Engl J Med. 1998 Mar 5;338(10):663-70. Review.</citation>
    <PMID>9486996</PMID>
  </reference>
  <reference>
    <citation>Kaltreider DF, Kohl S. Epidemiology of preterm delivery. Clin Obstet Gynecol. 1980 Mar;23(1):17-31. Review.</citation>
    <PMID>6988128</PMID>
  </reference>
  <reference>
    <citation>ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 80: premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol. 2007 Apr;109(4):1007-19.</citation>
    <PMID>17400872</PMID>
  </reference>
  <reference>
    <citation>Crowther CA, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003935. Review. Update in: Cochrane Database Syst Rev. 2011;(6):CD003935.</citation>
    <PMID>17636741</PMID>
  </reference>
  <reference>
    <citation>McNamara HC, Crowther CA, Brown J. Different treatment regimens of magnesium sulphate for tocolysis in women in preterm labour. Cochrane Database Syst Rev. 2015 Dec 14;(12):CD011200. doi: 10.1002/14651858.CD011200.pub2. Review.</citation>
    <PMID>26662716</PMID>
  </reference>
  <reference>
    <citation>Shatrov JG, Birch SCM, Lam LT, Quinlivan JA, McIntyre S, Mendz GL. Chorioamnionitis and cerebral palsy: a meta-analysis. Obstet Gynecol. 2010 Aug;116(2 Pt 1):387-392. doi: 10.1097/AOG.0b013e3181e90046. Review.</citation>
    <PMID>20664400</PMID>
  </reference>
  <reference>
    <citation>Weiner CP, Renk K, Klugman M. The therapeutic efficacy and cost-effectiveness of aggressive tocolysis for premature labor associated with premature rupture of the membranes. Am J Obstet Gynecol. 1988 Jul;159(1):216-22. Erratum in: Am J Obstet Gynecol 1991 Sep;165(3):785.</citation>
    <PMID>3134815</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Fathi Abdelraouf</investigator_full_name>
    <investigator_title>Ahmed Fathi Abdelraouf</investigator_title>
  </responsible_party>
  <keyword>Magnesium sulphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Fetal Membranes, Premature Rupture</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

